Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Cureus ; 15(8): e42941, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37667722

ABSTRACT

The social determinants of health (SDOH) are a complex web of factors that influence the health of individuals throughout their lifetime. There are many drivers of health inequities within the SDOH, such as socioeconomic status, education, employment, gender, and race/ethnicity. It is possible that mental illness may develop when these factors negatively affect health. However, current research primarily focuses on SDOH in cisgender individuals leaving a scientific gap in transgender individuals who require unique considerations when providing comprehensive medical care. We present the case of a 20-year-old transgender female who was admitted for suicidal attempts during a methamphetamine overdose, and who had been struggling with mental illness and suicidal gestures since she was a young teenager. The significance of our findings is discussed in the context of the substantial lack of current research on SDOH in transgender individuals to underscore the need for clinical awareness and promote future research.

2.
Cureus ; 13(7): e16335, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34395118

ABSTRACT

Research on the brain regions involved in suicidal behavior has led to the identification of a number of regions as being implicated in the neurobiology of suicide. Some of the brain regions identified have a clear correlation between the levels of activity and suicidal behavior. For some regions, such as the insular cortex and anterior cingulate cortex (ACC), both hyperactivity and hypoactivity have been correlated with suicidal behavior. More studies are needed to characterize more clearly the activity of the insular cortex and ACC when it comes to suicidal behavior. The case report presented adds to the literature seeking to clarify the correlation between ACC and insular activities and suicidal behavior. Structural damage of the insular region and ACC, thus leading to a decline in their activity level, was found in a patient who had resolution of suicidal intent after hypoxic brain injury. We discuss the significance of our findings for the neurobiology of suicide.

3.
Psychiatr Q ; 91(2): 561-570, 2020 06.
Article in English | MEDLINE | ID: mdl-32086668

ABSTRACT

Vitamin D is traditionally recognized for its role in bone mineralization but recent observations suggest additional pertinent functions in neuronal biology. The present study examines the rate and pattern of Vitamin D deficiency in the outpatient mental health clinic of a community teaching hospital as well as the vitamin D supplementation practices of outpatient psychiatrists. Participants include 148 consecutive psychiatric outpatients. Individuals with conditions that alter the metabolism of vitamin D were excluded from the study as are those who may be taking medications that influence Vitamin D metabolism. Statistical analysis was performed using the SPSS 25th edition, statistical significance set at p < 0.05. The majority of patients in the study were between 41 and 65 years old (n = 91, 61.5%), African American (n = 120, 81.1%) and female (n = 80, 54.1%). The median level is 23.7 ng/ml. As defined by the Endocrine Society's Clinical Practice Guidelines, 68.2% of the population had insufficient and deficient Vitamin D levels (32.4% and 35.8% respectively), 62.4% of whom were not prescribed any Vitamin D supplementation and of this untreated group, 84% were African Americans. No clinical or demographic characteristics showed any statistical difference in both the "treated" and "not treated groups". Logistic regression did not reveal any significant predictors for Vitamin D deficiency. Vitamin D deficiency remains a significant issue among patients with psychiatric disorders. Our findings show gaps in Vitamin D deficiency treatment and recommend that future studies examine physician prescription practices in light of the racial disparity in Vitamin D deficiency treatment oberved in this study.


Subject(s)
Community Mental Health Services/statistics & numerical data , Outpatients/statistics & numerical data , Vitamin D Deficiency/epidemiology , Adolescent , Adult , Black or African American/statistics & numerical data , Aged , Cohort Studies , Female , Humans , Male , Mental Disorders/drug therapy , Middle Aged , New York , Prevalence , Retrospective Studies , Vitamin D/therapeutic use , Vitamin D Deficiency/drug therapy , White People/statistics & numerical data , Young Adult
4.
Cureus ; 12(12): e11898, 2020 Dec 04.
Article in English | MEDLINE | ID: mdl-33415050

ABSTRACT

We present an unusual case of a middle-aged patient with a near-total loss of autobiographical memory; the memory of one's own personal history and personal identity following a motor vehicle accident. The nature of his autobiographical memory loss was anterograde and retrograde amnesia, with the preservation of procedural learning, including an extensive set of medical skills, which he attributed to his career as a psychiatrist. Of significance was the absence of any traumatic changes in the medial temporal lobe structures, hippocampal formation, amygdala, and entorhinal cortex on brain imaging. The significance of our findings is discussed in the context of the evolving theories of the role of medial temporal lobe structures in memory formation.

5.
Ann Intern Med ; 164(7): 472-8, 2016 Apr 05.
Article in English | MEDLINE | ID: mdl-26881842

ABSTRACT

BACKGROUND: The efficacy of erythropoietin-stimulating agents (ESAs) for improving health-related quality of life (HRQOL) in anemia of chronic kidney disease (CKD) is unclear. PURPOSE: To determine the effect of ESAs on HRQOL at different hemoglobin targets in adults with CKD who were receiving or not receiving dialysis. DATA SOURCES: Searches of PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov from inception to 1 November 2015, supplemented with manual screening. STUDY SELECTION: Randomized, controlled trials that evaluated the treatment of anemia with ESAs, including erythropoietin and darbepoetin, targeted higher versus lower hemoglobin levels, and used validated HRQOL metrics. DATA EXTRACTION: Study characteristics, quality, and data were assessed independently by 2 reviewers. Outcome measures were scores on the Short Form-36 Health Survey (SF-36), Kidney Dialysis Questionnaire (KDQ), and other tools. DATA SYNTHESIS: Of 17 eligible studies, 13 reported SF-36 outcomes and 4 reported KDQ outcomes. Study populations consisted of patients not undergoing dialysis (n = 12), those undergoing dialysis (n = 4), or a mixed sample (n = 1). Only 4 studies had low risk of bias. Pooled analyses showed that higher hemoglobin targets resulted in no statistically or clinically significant differences in SF-36 or KDQ domains. Differences in HRQOL were further attenuated in studies at low risk of bias and in subgroups of dialysis recipients. LIMITATION: Statistically significant heterogeneity among studies, few good-quality studies, and possible publication bias. CONCLUSION: ESA treatment of anemia to obtain higher hemoglobin targets does not result in important differences in HRQOL in patients with CKD. PRIMARY FUNDING SOURCE: KRESCENT and Manitoba Health Research Council Establishment.


Subject(s)
Anemia/drug therapy , Hematinics/therapeutic use , Quality of Life , Renal Insufficiency, Chronic/complications , Anemia/blood , Anemia/etiology , Hemoglobins/metabolism , Humans , Renal Dialysis , Renal Insufficiency, Chronic/therapy
6.
Am J Nephrol ; 41(2): 89-97, 2015.
Article in English | MEDLINE | ID: mdl-25721696

ABSTRACT

BACKGROUND: Anemia is a common complication associated with kidney failure and is marked by poor health and increased risk of morbidity and mortality. There are ongoing concerns with the use of Erythropoietin Stimulating Agents (ESAs) to treat anemia in patients with kidney failure on dialysis. Questions as to their benefits, harms and overall effect on quality of life are still relevant today. Our objective was to systematically review studies evaluating the cost-effectiveness of ESAs in patients with kidney failure on dialysis. METHODS: We performed a systematic review of studies determining the cost-effectiveness of ESAs in adult patients on dialysis. Databases, including PubMed, EMBASE, and Cochrane Database of Systematic Reviews, were searched from their establishment until June 2013. Studies that reported an incremental cost-effectiveness ratio of hemoglobin correction strategies based on ESA treatments in comparison to red blood cell transfusions, lower hemoglobin targets, or no ESA treatment were included. RESULTS: Seven studies met inclusion criteria. Reported cost/quality-adjusted life-year (QALY) ratios ranged from USD 931-677,749/QALY across five studies comparing ESAs to red blood cell transfusions. There was heterogeneity in results when considering higher hemoglobin targets, with studies finding higher targets to be both dominant and dominated. Mortality, hospitalization, and utility estimates were major drivers. CONCLUSIONS: There is substantial variability in the estimates of the cost-effectiveness of using ESAs in the dialysis population. New models incorporating recent meta-analyses for estimates of utility, mortality, and hospitalization changes would allow for a more comprehensive answer to this question.


Subject(s)
Anemia/therapy , Hematinics/economics , Hematinics/therapeutic use , Renal Dialysis/adverse effects , Renal Insufficiency, Chronic/complications , Cost-Benefit Analysis , Erythrocyte Transfusion/economics , Hemoglobins/metabolism , Humans , Quality-Adjusted Life Years , Renal Insufficiency, Chronic/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...